BioCentury
ARTICLE | Company News

Medigene licenses co-stimulator from Helmholtz to overcome checkpoint blockade with TCRs

January 11, 2019 6:57 PM UTC

Medigene AG (Xetra:MDG1) received exclusive, worldwide rights to a chimeric co-stimulatory receptor from Helmholtz Zentrum München (Neuherberg, Germany) for therapeutic and diagnostic use in TCR therapies and DC vaccines. Helmholtz designed the co-stimulator, a fusion protein comprising PD-1 and 4-1BB ligand (4-1BBL; TNFSF9; CD137L), to help T cells overcome checkpoint blockade in solid tumors.

Medigene will evaluate the chimeric co-stimulator receptor in combination with its TCRs for solid tumors, starting with preclinical studies...